BRPI0810096A8 - Anticorpo anti-epcam e seus usos - Google Patents

Anticorpo anti-epcam e seus usos

Info

Publication number
BRPI0810096A8
BRPI0810096A8 BRPI0810096A BRPI0810096A BRPI0810096A8 BR PI0810096 A8 BRPI0810096 A8 BR PI0810096A8 BR PI0810096 A BRPI0810096 A BR PI0810096A BR PI0810096 A BRPI0810096 A BR PI0810096A BR PI0810096 A8 BRPI0810096 A8 BR PI0810096A8
Authority
BR
Brazil
Prior art keywords
epcam antibody
diagnostic
designated
epcam
antibody
Prior art date
Application number
BRPI0810096A
Other languages
English (en)
Portuguese (pt)
Inventor
Maria Anastasi Anna
Petronzelli Fiorella
De Santis Rita
Alberti Saverio
Original Assignee
Sigma Tau Ind Farmaceuti
Alfasigma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti, Alfasigma Spa filed Critical Sigma Tau Ind Farmaceuti
Publication of BRPI0810096A2 publication Critical patent/BRPI0810096A2/pt
Publication of BRPI0810096A8 publication Critical patent/BRPI0810096A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0810096A 2007-04-04 2008-04-02 Anticorpo anti-epcam e seus usos BRPI0810096A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07105628 2007-04-04
PCT/EP2008/053913 WO2008122551A2 (en) 2007-04-04 2008-04-02 Anti-epcam antibody and uses thereof

Publications (2)

Publication Number Publication Date
BRPI0810096A2 BRPI0810096A2 (pt) 2014-10-21
BRPI0810096A8 true BRPI0810096A8 (pt) 2017-12-26

Family

ID=38458122

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0810096A BRPI0810096A8 (pt) 2007-04-04 2008-04-02 Anticorpo anti-epcam e seus usos

Country Status (21)

Country Link
US (1) US8318911B2 (cg-RX-API-DMAC7.html)
EP (1) EP2142570B1 (cg-RX-API-DMAC7.html)
JP (1) JP5631733B2 (cg-RX-API-DMAC7.html)
KR (1) KR101683884B1 (cg-RX-API-DMAC7.html)
CN (1) CN101970497B (cg-RX-API-DMAC7.html)
AT (1) ATE512988T1 (cg-RX-API-DMAC7.html)
AU (1) AU2008235566B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0810096A8 (cg-RX-API-DMAC7.html)
CA (1) CA2682296C (cg-RX-API-DMAC7.html)
CY (1) CY1111819T1 (cg-RX-API-DMAC7.html)
DK (1) DK2142570T3 (cg-RX-API-DMAC7.html)
EA (1) EA023679B1 (cg-RX-API-DMAC7.html)
ES (1) ES2367675T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20110620T1 (cg-RX-API-DMAC7.html)
IL (1) IL201196A0 (cg-RX-API-DMAC7.html)
MX (1) MX2009010444A (cg-RX-API-DMAC7.html)
PL (1) PL2142570T3 (cg-RX-API-DMAC7.html)
PT (1) PT2142570E (cg-RX-API-DMAC7.html)
RS (1) RS52040B (cg-RX-API-DMAC7.html)
SI (1) SI2142570T1 (cg-RX-API-DMAC7.html)
WO (1) WO2008122551A2 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2513747C (en) 2003-01-24 2017-03-07 University Of Utah Methods of predicting mortality risk by determining telomere length
AU2009329987B2 (en) 2008-12-22 2016-08-04 University Of Utah Research Foundation Monochrome multiplex quantitative PCR
GB0909904D0 (en) * 2009-06-09 2009-07-22 Affitech As Product
CN103561771B (zh) 2011-03-17 2019-01-04 伯明翰大学 重新定向的免疫治疗
JP6400470B2 (ja) * 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
CN110763842A (zh) 2011-06-29 2020-02-07 中央研究院 使用表面涂层对生物物质的捕获、纯化和释放
EP2819695B1 (en) * 2012-03-02 2018-06-27 Academia Sinica ANTI-EPITHELIAL CELL ADHESION MOLECULE (EpCAM) ANTIBODIES AND METHODS OF USE THEREOF
US9494500B2 (en) 2012-10-29 2016-11-15 Academia Sinica Collection and concentration system for biologic substance of interest and use thereof
JP6546158B2 (ja) 2013-05-22 2019-07-17 テロメア ダイアグノスティクス インコーポレイテッド 短いテロメアの存在量の測定
EP3126814B1 (en) 2014-04-01 2019-06-12 Academia Sinica Methods and systems for cancer diagnosis and prognosis
EP2998026B1 (en) 2014-08-26 2024-01-17 Academia Sinica Collector architecture layout design
CN107208145A (zh) 2014-12-30 2017-09-26 端粒诊断公司 多重定量pcr
EP3328897A1 (en) * 2015-07-31 2018-06-06 Sutro Biopharma, Inc. ANTI-EpCAM ANTIBODIES, COMPOSITIONS COMPRISING ANTI-EpCAM ANTIBODIES AND METHODS OF MAKING AND USING ANTI-EPCAM ANTIBODIES
US10107726B2 (en) 2016-03-16 2018-10-23 Cellmax, Ltd. Collection of suspended cells using a transferable membrane
WO2017173091A1 (en) * 2016-03-30 2017-10-05 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
US20190262397A1 (en) 2016-07-26 2019-08-29 Tessa Therapeutics Pte. Ltd. Chimeric antigen receptor
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
AU2019402097A1 (en) 2018-12-17 2021-06-10 Revitope Limited Twin immune cell engager
CN113597432B (zh) * 2019-04-22 2023-05-02 江苏恒瑞医药股份有限公司 抗EpCAM抗体及其应用
CN114026127B (zh) 2019-06-11 2024-10-29 生物蛋白有限公司 条件活性抗epcam抗体、抗体片段、其免疫缀合物以及其用途
CN110950959B (zh) * 2020-02-25 2020-07-03 和铂医药(上海)有限责任公司 靶向EpCAM的抗体及其制备和应用
CN112094350B (zh) * 2020-06-01 2024-01-05 普众发现医药科技(上海)有限公司 可应用于肿瘤细胞捕获的小鼠抗细胞表面糖蛋白cd326的单克隆抗体
WO2022037323A1 (zh) * 2020-08-19 2022-02-24 上海易慕峰生物科技有限公司 人源化抗体、嵌合抗原受体、核酸、载体、细胞及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US5525338A (en) 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
IT1245748B (it) 1990-12-21 1994-10-14 Mini Ricerca Scient Tecnolog Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego
US5578287A (en) * 1992-06-09 1996-11-26 Neorx Corporation Three-step pretargeting methods using improved biotin-active agent
JP3427871B2 (ja) * 1996-06-24 2003-07-22 戸田工業株式会社 コバルト被着型針状磁性酸化鉄粒子粉末
ITRM20010079A1 (it) 2001-02-16 2002-08-16 Sigma Tau Ind Farmaceuti Amminoderivati della biotina e loro coniugati con chelanti macrociclici.
US20050180979A1 (en) * 2004-02-13 2005-08-18 Micromet Ag Anti-EpCAM immunoglobulins
US7435804B2 (en) * 2004-10-19 2008-10-14 Phage Biotechnology, Inc. Method for obtaining single chain antibodies to human interferon α2b

Also Published As

Publication number Publication date
KR20100016237A (ko) 2010-02-12
RS52040B (sr) 2012-04-30
JP5631733B2 (ja) 2014-11-26
PL2142570T3 (pl) 2011-11-30
AU2008235566B2 (en) 2013-06-06
ES2367675T3 (es) 2011-11-07
PT2142570E (pt) 2011-09-13
WO2008122551A9 (en) 2009-02-05
KR101683884B1 (ko) 2016-12-07
IL201196A0 (en) 2010-05-17
EP2142570B1 (en) 2011-06-15
US8318911B2 (en) 2012-11-27
JP2010523096A (ja) 2010-07-15
AU2008235566A1 (en) 2008-10-16
EA023679B1 (ru) 2016-06-30
CN101970497B (zh) 2017-05-10
EP2142570A2 (en) 2010-01-13
CA2682296A1 (en) 2008-10-16
MX2009010444A (es) 2009-10-20
CA2682296C (en) 2017-02-28
CN101970497A (zh) 2011-02-09
US20100092491A1 (en) 2010-04-15
SI2142570T1 (sl) 2012-01-31
CY1111819T1 (el) 2015-10-07
ATE512988T1 (de) 2011-07-15
EA200970923A1 (ru) 2010-04-30
WO2008122551A2 (en) 2008-10-16
BRPI0810096A2 (pt) 2014-10-21
HRP20110620T1 (hr) 2011-09-30
DK2142570T3 (da) 2011-10-03
WO2008122551A3 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
BRPI0810096A8 (pt) Anticorpo anti-epcam e seus usos
CO2021002907A2 (es) Constructos de anticuerpos para cldn18.2 y cd3
MX386942B (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
BR112018071307A2 (pt) anticorpos agonistas que ligam cd40 humana e usos dos mesmos
BRPI0611800A2 (pt) formulaÇço estÁvel de anticorpo
PA8794201A1 (es) Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso
BRPI0906478B8 (pt) anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende
BR112016007112A2 (pt) Anticorpos que se ligam a angiopoietina 2 (ang-2) humana, usos de um anticorpo que se liga a angiopoietina 2 (ang-2) humana e combinação
CY1118763T1 (el) Αντισωμα αντι-ερηα2
AR078751A1 (es) Moleculas de anticuerpo anti-gcc (guanililo ciclasa c) y composiciones y metodos relacionados
BR112018014615A2 (pt) composições de anticorpo para ror1 e métodos relacionados
BR112017000671A2 (pt) moléculas com especificidade para cd79 e cd22
BR112015017548A8 (pt) construção de anticorpo multiespecífico isolado, sequência de ácido nucléico, vetor, célula hospedeira, processo para a produção da construção de anticorpo, composição farmaceutica, uso da construção de anticorpo e kit
BR112013033258A2 (pt) moléculas de ligação de anti-alfa sinucleína
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
BRPI0416141B8 (pt) anticorpo anti-cd52 modificado, composição farmacêutica, vetores de expressão, e método para preparar uma imunoglobulina
CO6351750A2 (es) Composiciones y métodos para anticuerpos que se dirigen a la proteina de complementos c5
EA201201533A1 (ru) Prlr-специфическое антитело и его применения
BR112014026740A2 (pt) anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
BR112013027829A2 (pt) anticorpos anti-cd40 e método de uso
ECSP088636A (es) Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos, y métodos de uso en la terapia de cáncer
BR112016014413A2 (pt) glicosiltransferase que glicosila o ácido flavoquermésico e/ou ácido quermésico
BRPI0607323B8 (pt) composições, usos de polipeptídeos e de anticorpos, bem como kits para a detecção de anticorpo que se liga especificamente a um polipeptídeo
BR112012013581A2 (pt) vacinas de malária baseadas em ferlinas apicomplexas, proteínas semelhante a ferlinas e outras proteínas que contêm o domínio c2
BR112023020802A2 (pt) Polipeptídeo de ligação a gucy2c e usos do mesmo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: ALFASIGMA S.P.A. (IT)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL

B350 Update of information on the portal [chapter 15.35 patent gazette]